LRRK2 in Early Parkinson's Disease

Clinical Trial Title

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease (283PD201)

National Clinical Trial Number:


Contact Information

Katie Kompoliti, MD, or Tila Warner-Rosen

Clinical Trial Protocol Description:

The purpose of this study is to look at whether a study drug works in people with early-stage Parkinson’s disease (PD), how safe it is in terms of medical problems known as “side effects”, and how the body handles taking it (tolerability). 

Participation will last a minimum of approximately 55 weeks and a maximum of 152 weeks in total. During your participation, you will need to attend up to 20 visits at the study site. You will also be asked to have various tests done and answer questionnaires in clinic at at home. 

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are 30-80 years of age.
  • Have a clinical diagnosis of Parkinson's disease (PD) within the last 2 years.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a clinically significant neurological diagnosis, other than PD, in the last 5 years.
  • Have previously or are currently participating in a gene therapy trial.
  • Have a history of brain surgical intervention for PD (e.g., deep-brain stimulation, pallidotomy).

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Katie Kompoliti, MD

Contact Information

Katie Kompoliti, MD, or Tila Warner-Rosen

Clinical Trial Location

RUSH University Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more